Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
1995-9-14
|
pubmed:abstractText |
A prospective, randomized trial was initiated in adult acute lymphoblastic leukemia (ALL) to compare (1) disease-free survival (DFS) after allogeneic or autologous bone marrow transplantation (BMT) and (2) the relapse rate of patients treated with or without interleukin-2 (IL-2) after autologous BMT. A total of 135 previously untreated patients, aged under 55 years, received the Berlin-Frankfurt-Muster (BFM) induction regimen: 126 patients (93%), of which 120 were HLA-typed, achieved complete remission (CR). According to this genetic randomization, patients with (n = 43) or without an HLA-identical sibling (n = 77) were to receive allogeneic or autologous BMT, respectively. The 3-year post-CR probability of DFS was significantly higher in the HLA-identical sibling group than in the non-HLA-identical sibling group (68% v 26%; P < .001). Eligible patients were randomized to receive (n = 30) or not to receive (n = 30) IL-2 after autologous BMT: the 3-year post-BMT probability of continuous CR was similar in both groups (29% v 27%, respectively). We conclude that, in ALL, early allogeneic BMT after the BFM induction regimen is an effective consolidation treatment and that IL-2 does not decrease the high relapse rate observed after autologous BMT.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
0006-4971
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
15
|
pubmed:volume |
86
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
N
|
pubmed:pagination |
1619-28
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:7632972-Adult,
pubmed-meshheading:7632972-Bone Marrow Transplantation,
pubmed-meshheading:7632972-Combined Modality Therapy,
pubmed-meshheading:7632972-HLA Antigens,
pubmed-meshheading:7632972-Histocompatibility,
pubmed-meshheading:7632972-Humans,
pubmed-meshheading:7632972-Immunophenotyping,
pubmed-meshheading:7632972-Interleukin-2,
pubmed-meshheading:7632972-Middle Aged,
pubmed-meshheading:7632972-Precursor Cell Lymphoblastic Leukemia-Lymphoma,
pubmed-meshheading:7632972-Prospective Studies,
pubmed-meshheading:7632972-Survival Analysis,
pubmed-meshheading:7632972-Transplantation, Autologous,
pubmed-meshheading:7632972-Transplantation, Homologous
|
pubmed:year |
1995
|
pubmed:articleTitle |
Consolidation treatment of adult acute lymphoblastic leukemia: a prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. BGMT Group.
|
pubmed:affiliation |
Department of Hematology, Hôpital Purpan, Toulouse, France.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Multicenter Study
|